Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab
OMM measures characterise the metabolic heterogeneity in stage 2 diabetes, identifying differences between rapid- and slow-progressors, and heterogeneous impacts of immunotherapy, suggesting the need to account for these differences when designing and interpreting clinical trials.
Authors
- Antoinette Moran (ORCID: https://orcid.org/0000-0002-2694-5147)
- Kevan C. Herold (ORCID: https://orcid.org/0000-0003-1534-6613)
- Emily K. Sims (ORCID: https://orcid.org/0000-0002-4393-954X)
- Heba M. Ismail (ORCID: https://orcid.org/0000-0003-0102-0030)
- David D Cuthbertson (ORCID: https://orcid.org/0000-0002-3785-9834)
- Carmella Evans‐Molina (ORCID: https://orcid.org/0000-0001-7764-8663)
- Alessandra Petrelli (ORCID: https://orcid.org/0000-0002-5639-9415)
- Brandon M. Nathan (ORCID: https://orcid.org/0000-0001-6405-3994)
- Alfonso Galderisi (ORCID: https://orcid.org/0000-0001-8885-3056)
Institutions
- University of Minnesota (US)
- University of Milan (IT)
- University of South Florida (US)
- Yale University (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Diabetologia
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1007/s00125-024-06323-0
- Citations
- 10
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 5.50
Funders
- John Templeton Foundation
- Immune Tolerance Network
- MacroGenics
- National Center for Research Resources
- Division of Diabetes, Endocrinology, and Metabolic Diseases